Logo image of IRON

DISC MEDICINE INC (IRON) Stock Fundamental Analysis

NASDAQ:IRON - Nasdaq - US2546041011 - Common Stock - Currency: USD

60.61  +0.03 (+0.05%)

After market: 60.61 0 (0%)

Fundamental Rating

2

IRON gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. While IRON seems to be doing ok healthwise, there are quite some concerns on its profitability. IRON is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IRON has reported negative net income.
In the past year IRON has reported a negative cash flow from operations.
In the past 5 years IRON always reported negative net income.
IRON had a negative operating cash flow in each of the past 5 years.
IRON Yearly Net Income VS EBIT VS OCF VS FCFIRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of IRON (-16.42%) is better than 80.40% of its industry peers.
Looking at the Return On Equity, with a value of -17.64%, IRON belongs to the top of the industry, outperforming 86.51% of the companies in the same industry.
Industry RankSector Rank
ROA -16.42%
ROE -17.64%
ROIC N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
IRON Yearly ROA, ROE, ROICIRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

IRON does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRON Yearly Profit, Operating, Gross MarginsIRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IRON has more shares outstanding
The debt/assets ratio for IRON is higher compared to a year ago.
IRON Yearly Shares OutstandingIRON Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IRON Yearly Total Debt VS Total AssetsIRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

IRON has an Altman-Z score of 25.62. This indicates that IRON is financially healthy and has little risk of bankruptcy at the moment.
IRON has a Altman-Z score of 25.62. This is amongst the best in the industry. IRON outperforms 95.50% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that IRON is not too dependend on debt financing.
IRON's Debt to Equity ratio of 0.04 is on the low side compared to the rest of the industry. IRON is outperformed by 61.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 25.62
ROIC/WACCN/A
WACCN/A
IRON Yearly LT Debt VS Equity VS FCFIRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

IRON has a Current Ratio of 37.65. This indicates that IRON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 37.65, IRON belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
A Quick Ratio of 37.65 indicates that IRON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 37.65, IRON belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 37.65
Quick Ratio 37.65
IRON Yearly Current Assets VS Current LiabilitesIRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IRON have decreased strongly by -18.43% in the last year.
EPS 1Y (TTM)-18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IRON is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.09% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.13%
EPS Next 2Y-13.91%
EPS Next 3Y-1.57%
EPS Next 5Y18.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IRON Yearly Revenue VS EstimatesIRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IRON Yearly EPS VS EstimatesIRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRON. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRON. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRON Price Earnings VS Forward Price EarningsIRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRON Per share dataIRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.91%
EPS Next 3Y-1.57%

More info and screens

0

5. Dividend

5.1 Amount

IRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DISC MEDICINE INC

NASDAQ:IRON (7/25/2025, 8:00:01 PM)

After market: 60.61 0 (0%)

60.61

+0.03 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners85.98%
Inst Owner Change0.16%
Ins Owners0.35%
Ins Owner Change3.6%
Market Cap2.10B
Analysts84.71
Price Target100.24 (65.39%)
Short Float %11.27%
Short Ratio8.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.24%
Min EPS beat(2)11.71%
Max EPS beat(2)12.77%
EPS beat(4)4
Avg EPS beat(4)12.69%
Min EPS beat(4)9.14%
Max EPS beat(4)17.14%
EPS beat(8)6
Avg EPS beat(8)9.41%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.93%
PT rev (3m)-0.13%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)2.9%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)4.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.18
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-3.92
EYN/A
EPS(NY)-5.18
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.94
OCFYN/A
SpS0
BVpS19.07
TBVpS19.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.42%
ROE -17.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.05%
ROA(5y)-23.6%
ROE(3y)-24.43%
ROE(5y)-26.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 859.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.65
Quick Ratio 37.65
Altman-Z 25.62
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)193.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.42%
EPS Next Y-20.13%
EPS Next 2Y-13.91%
EPS Next 3Y-1.57%
EPS Next 5Y18.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.42%
EBIT Next 3Y16.66%
EBIT Next 5YN/A
FCF growth 1Y-60.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.86%
OCF growth 3YN/A
OCF growth 5YN/A